Abstract 598
Background
U.S. Food and Drug Administration (FDA) approves drugs based on overall survival (OS) in oncology trials in order to speed up access of novel drugs to the market.
Methods
We examined all adult anticancer drugs approved by the FDA from Jan’2006 to Jan’2019. Data regarding the approval type (regular or accelerated), cancer type, treatment indication, and basis for approval were extracted from the FDA website and any relevant publications. The basis for approval was categorized into the response rate (RR), progression-free survival (PFS), and overall survival (OS) endpoints and their analysis. Approvals for pediatric cancers, biosimilars, and cancers limited to genetic syndromes were not included in this study.
Results
A total of 258 FDA approvals were analyzed, of which 57 (22.09%) were approved for first-line therapy and 201 (77.91%) for subsequent lines. Sixty-six (25.58%) were approved based on the OS endpoint, 23 (8.91%) in the first line and 43 (16.67%) in the subsequent lines. One hundred ninety-two (74.42%) drugs were granted approval (regular and accelerated) based on surrogate endpoints: 104 (40.31%) of them for RR and 87 (33,72%) for PFS. Thirteen (5.04%) and 91 (35.27%) were approved for RR, and 20 (7.75%) and 67 (25.97%) were approved for PFS in the first and subsequent lines, respectively (Table). Table Out of the total 258 FDA approvals, 66 (25.58%) were accelerated and 192 (74.42%) regular. Ten (3.88%) and 56 (21.71%) obtained accelerated approval in the first and subsequent lines, respectively. Forty-seven (18.22%) and 145 (56.20%) were granted regular approval in the first and subsequent lines, respectively.Table:
486P
Lines of treatment | # of approvals for RR (%) | # of approvals for PFS (%) | # of approvals for OS (%) | Total # of approvals (%) |
---|---|---|---|---|
First line | 13 (5.04) | 20 (7.75) | 23 (8.91) | 57 (22.09) |
Subsequent lines | 91 (35.27) | 67 (25.97) | 43 (16.17) | 201 (77.91) |
Total | 104 (40.31) | 87 (33.72) | 66 (25.58) | 258 (100) |
Conclusions
RR and PFS were the most frequently approved surrogate endpoints, most often for use in later lines of therapy. The accelerated approvals based on surrogate endpoints in later lines of therapy represent a topic of current debate.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2831 - Interleukin-6 as a Predictive Marker for Early Response to Induction Chemotherapy in Acute Myeloblastic Leukaemia
Presenter: Salah Khallaf
Session: Poster Display session 1
Resources:
Abstract
6014 - Impact of FLT3-ITD mutation on post-transplant outcome of adult AML is modified by the concomitant NPM1 mutation and pre-transplant remission status: A report from Taiwan Bone Marrow Transplant Registry (TBMTR)
Presenter: Su-peng Yeh
Session: Poster Display session 1
Resources:
Abstract
2914 - Efficacy endpoints studied in clinical trials for early-onset leukaemia
Presenter: Dylan Said
Session: Poster Display session 1
Resources:
Abstract
4691 - High triglyceride is a major risk factor of DIC and differentiation syndrome in acute promyelocytic leukemia
Presenter: Tomohiro Yamakawa
Session: Poster Display session 1
Resources:
Abstract
4395 - DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Presenter: Suzanne Trudel
Session: Poster Display session 1
Resources:
Abstract
2808 - A Phase 1 Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Nathan Fowler
Session: Poster Display session 1
Resources:
Abstract
4403 - A Phase 1 Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Patients with Relapsed or Refractory Lymphoma
Presenter: Jonathon Cohen
Session: Poster Display session 1
Resources:
Abstract
3357 - A global patient-driven Facebook study in a very rare sarcoma: Health-related quality of life in Epithelioid Hemangioendothelioma (EHE) patients
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
2475 - Qualitative study of patients’ experiences of living with and beyond a soft tissue sarcoma diagnosis: the impact of sarcoma specialist services
Presenter: Ana Martins
Session: Poster Display session 1
Resources:
Abstract
2640 - Health-related quality of life issues of patients affected by desmoid-type fibromatosis; experiences from two countries
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract